Ingevity (NGVT) drew fresh attention after announcing that its Evotherm P35 warm mix asphalt additive received approval from Germany’s Federal Highway Research Institute, opening potential access to one of Europe’s stricter road materials markets.

At a share price of $74.70, Ingevity has delivered a 24.31% year to date share price return and a 60.20% total shareholder return over the past year. This suggests that momentum has been building recently despite some mixed shorter term moves.

If this kind of product driven story has your attention, it could be a good moment to broaden your search using the 36 power grid technology and infrastructure stocks

After a strong 1 year run, Ingevity now sits well below the average analyst target and at a large discount to some intrinsic value estimates. Where does a fair value range genuinely land for this stock today?

Most Popular Narrative: 16.1% Undervalued

Compared with the current Ingevity share price of $74.70, the most followed narrative points to a fair value of $89, suggesting a meaningful valuation gap built on detailed earnings and margin assumptions.

Accelerated portfolio repositioning and the advanced-stage divestiture of non-core, lower-margin businesses (Industrial Specialties and CTO refinery) are expected to drive a step-change in margin profile, enabling greater focus and capital allocation toward higher-growth, value-added specialty chemicals, supporting both revenue quality and sustained EBITDA margin improvement.

Want to see what kind of margin rebuild sits behind that $89 figure? The narrative leans on a sharp earnings turnaround, richer mix, and a very specific future profit multiple.

Result: Fair Value of $89 (UNDERVALUED)

However, this Ingevity narrative could be pressured if weakness in Advanced Polymer Technologies persists, or if tariff related demand issues further strain revenue and margins.

Another View: Ingevity Looks Expensive On Sales

While the popular Ingevity narrative leans on future earnings power and a fair value of $89, the current P/S ratio of 2.2x tells a tougher story. It sits well above the US Chemicals industry at 1.1x and also above a fair ratio of 1.5x, which points to higher valuation risk if those growth and margin assumptions do not play out.

To see how those sales based signals stack up against a cash flow driven view, take a closer look at the SWS DCF model for Ingevity, which gives a very different picture of value, using the See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

With mixed signals on value, risks and rewards, the real question is how Ingevity fits your own plan, so move quickly to review the data in detail and weigh the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Ingevity?

If Ingevity has sharpened your focus on quality opportunities, do not stop here. Use the Simply Wall Street Screener to uncover more targeted stock ideas today.

• Spot potential bargains early by scanning a curated set of screener containing 20 high quality undiscovered gems before they move onto everyone else's radar.
• Prioritize resilience and sleep easier at night by filtering for 82 resilient stocks with low risk scores that align with your comfort level.
• Focus on financial strength first by zeroing in on companies from the solid balance sheet and fundamentals stocks screener (49 results) that can better withstand tough conditions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.